The Latest Breaking News from Moderna

The biotech company's experimental Omicron booster generates high levels of antibodies that neutralise subvariants BA.4 and BA.5, according to preliminary clinical trial data.

NPR talks to Claire Hannan, who has helped navigate vaccine rollouts in all 50 states, about some of the challenges involved in quickly getting shots out to millions of young kids.

CDC advisers are recommending the use of two separate COVID-19 vaccines for the youngest children made by Moderna and Pfizer-BioNTech, paving the way for vaccine rollout as early as next week.

Covid-19 cases in Irish hospitals have rose rapidly over the past two weeks, with 508 people currently in hospital with the virus

U.S. kids under 5 — roughly 18 million youngsters — are eligible for the shots.

The vaccinations for children as young as 6 months old could start next week. But first, the Centers for Disease Control and Prevention must sign off.

Moderna's (NASDAQ:MRNA) short percent of float has risen 11.96% since its last report. The company recently reported that it has 17.06 million shares sold short, which is 4.96% of all regular shares that are available for trading.

A modified coronavirus vaccine that targets the Omicron variant can be administered as a booster dose to broaden immunity, a technical advisory group set up the World Health Organization said on Friday. Such a variant-adapted vaccine may benefit those who have already received the primary series of shots, the agency's…

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.